Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1
- 1 August 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 17 (8) , 1748-1758
Abstract
Lung cancer is a heterogeneous disease in which patient-specific treatments are desirable and the development of targeted therapies has been effective. Although mutations in KRAS are frequent in lung adenocarcinoma, there are currently no targeted agents against KRAS. Using a mouse lung adenocarcinoma cell line with a Kras mutation (CMT167), we previously showed that PPARγ activation in lung cancer cells inhibits cell growth in vitro yet promotes tumor progression when activated in myeloid cells of the tumor microenvironment. Here, we report that PPARγ activation in myeloid cells promotes the production of TGFβ1, which, in turn, acts on CMT167 cancer cells to increase migration and induce an epithelial–mesenchymal transition (EMT). Targeting TGFβ1 signaling in CMT167 cells prevented their growth and metastasis in vivo. Similarly, another mouse lung adenocarcinoma cell line with a Kras mutation, LLC, induced TGFβ1 in myeloid cells through PPARγ activation. However, LLC cells are more mesenchymal and did not undergo EMT in response to TGFβ1, nor did LLC require TGFβ1 signaling for metastasis in vivo. Converting CMT167 cells to a mesenchymal phenotype through overexpression of ZEB1 made them unresponsive to TGFβ1 receptor inhibition. The ability of TGFβ1 to induce EMT in lung tumors may represent a critical process in cancer progression. We propose that TGFβ receptor inhibition could provide an additional treatment option for KRAS-mutant epithelial lung tumors. Implications: This study suggests that TGFβ receptor inhibitors may be an effective therapy in a subset of KRAS-mutant patients with non–small cell lung cancer, which show an epithelial phenotype.Keywords
All Related Versions
Funding Information
- NCI (R01 CA162226, CA108610)
- University of Colorado Cancer Center SPORE in Lung Cancer (P50 CA058187)
- VA Career Development (CDA IK2BX001282)
- Ruth L. Kirschstein National Research Service (T32CA17468)
- NCI (P30CA046934)
This publication has 42 references indexed in Scilit:
- Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell CarcinomaClinical Cancer Research, 2012
- Activation of PPARγ in Myeloid Cells Promotes Lung Cancer Progression and MetastasisPLOS ONE, 2011
- The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung CarcinogenesisCancer Microenvironment, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Targeted Therapies in Lung CancerSurgical Pathology Clinics, 2010
- Depletion of Cytosolic Phospholipase A2 in Bone Marrow–Derived Macrophages Protects against Lung Cancer Progression and MetastasisCancer Research, 2009
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008
- TGFβ in CancerCell, 2008
- Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cellsProstaglandins, Leukotrienes and Essential Fatty Acids, 2007
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002